Resectable pancreatic adenocarcinoma neo-adjuvant folf(irin)ox-based chemotherapy – a multicenter, non-comparative, randomized, phase ii trial (panache01-prodige48 study)

HIGHLIGHTS

  • who: Lilian Schwarz and colleagues from the Department of Digestive Surgery, Hu00f4pital Charles Nicolle, Rouen, France UNIROUEN, UMR , INSERM, Rouen University Hospital, Department of have published the Article: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study), in the Journal: (JOURNAL)
  • what: The aim of the trial is to evaluate the feasibility and efficacy of two regimens of neoadjuvant chemotherapy. CT scan: Patients eligible for this study have resectable PDAC as shown on CT scan of thorax, abdomen and pelvis with IV contrast . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?